FIG. 3.
Replication-defective adenoviral vector expressing CD40L. (a) Growth curve of established subcutaneous B16ova tumors in immunocompetent mice (n = 8 mice per group) after six intratumoral treatments with Ad-GFP and Ad-CD40L (1 × 109 PFU per dose). (b) Kaplan–Meier plot of immunocompetent mice harboring subcutaneous B16ova tumors after treatment consisting of two intratumoral administrations of either Ad-GFP (given on days 7 and 8) or Ad-CD40L (given on days 7 and 8). Both adenovectors were given at a dose of 1 × 109 PFU. (c) Spleens from mice with regressing AdCD40L-treated tumors were harvested 15 days after tumor challenge, along with those of control-treated mice. The splenocytes were stained with MHC class I murine tetramer SA–PE H2Kb-OVA and anti-CD8–FITC and subjected to flow cytometry. *p < 0.05, ***p < 0.001.